Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Microglial EZH2 inhibition may protect against stroke damage

April 6, 2021

FDA issues complete response letter for sNDA of pimavanserin

April 6, 2021

Phase II data reported for GV-1001 in moderate to severe Alzheimer's disease

April 6, 2021

Tsukushi protein mutations can lead to hydrocephalus

April 1, 2021

Dosing begins in phase Ib study of FX-301 for management of postoperative pain

April 1, 2021

Squalenoyl siRNA PMP22 nanoparticles developed for Charcot-Marie-Tooth disease type 1 A

March 31, 2021

New model of MECP2 duplication syndrome may advance antisense oligonucleotide treatment

March 31, 2021

Wave ends clinical development of WVE-120102 and WVE-120101 for Huntington's disease

March 31, 2021

E.U. approval granted to Kesimpta for relapsing MS

March 30, 2021

European Commission approves Evrysdi for spinal muscular atrophy

March 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...